Author/Authors :
Iravani, Shahrokh Research Center for Cancer Screening and Epidemiology - AJA University of Medical Sciences - Tehran, Iran , Dooghaie-Moghadam, Arash Liver Transplantation Research Center - Tehran University of Medical Sciences - Tehran, Iran , Razavi-Khorasani, Niloofar Liver Transplantation Research Center - Tehran University of Medical Sciences - Tehran, Iran , Moazzami, Bobak Liver Transplantation Research Center - Tehran University of Medical Sciences - Tehran, Iran , Dowlati Beirami, Amirreza Gastroenterology and Liver Diseases Research Center - Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Mansour-Ghanaei, Alireza Gastroenterology and Liver Diseases Research Center - Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Majidzadeh-A, Keivan Research Center for Cancer Screening and Epidemiology - AJA University of Medical Sciences - Tehran, Iran , Mehrvar, Azim Research Center for Cancer Screening and Epidemiology - AJA University of Medical Sciences - Tehran, Iran , Khoshdel, Alireza Research Center for Cancer Screening and Epidemiology - AJA University of Medical Sciences - Tehran, Iran , Nasiri Toosi , Mohssen Liver Transplantation Research Center - Tehran University of Medical Sciences - Tehran, Iran , Sadeghi, Amir Gastroenterology and Liver Diseases Research Center - Research Institute for Gastroenterology and Liver Diseases - Shahid Beheshti University of Medical Sciences - Tehran, Iran
Abstract :
Primary sclerosing cholangitis is a chronic cholestatic liver disease defined by strictures of the biliary tree which could ultimately lead to liver cirrhosis and cholangiocarcinoma. Although the exact underlying etiology of this disorder is not fully understood, the pathology is believed to be caused by immune mediated mechanisms. Growing body of evidence suggests several treatment modalities mainly focusing on the inflammation aspect of this disorder. However, there is still no consensus regarding the best treatment option for these patients. Thus, the present study aimed to review the current treatment options for patients with primary sclerosing cholangitis.
Keywords :
Cholangitis , Inflammatory bowel disease , Primary sclerosing cholangitis (PSC) , Management , Vancomycin , Cholestasis
